ADC Therapeutics is a commercial-stage biotechnology enterprise dedicated to researching, developing, and commercializing innovative targeted oncology medications. Headquartered in Epalinges, Switzerland, with operational offices in the United States, the company specializes in advancing proprietary antibody-drug conjugates to treat difficult hematological malignancies and solid tumors. Its portfolio features FDA-approved therapies like Zynlonta, alongside active clinical pipelines targeting significant unmet medical needs in cancer care.